Stock listing
NASDAQ:IMVT Immunovant, Inc. Stock
Home listing (NASDAQ) of Immunovant, Inc.
Follow Immunovant, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:IMVT
$31.77 USD -1.40 (-4.2%)
Close on Nov 20, 2026
- Day range
- $31.62 – $32.77 USDNov 20, 2026
- Volume
- 702,865 sharesNov 20, 2026
- Market cap
- $6.57B USDAt the close on Nov 20, 2026 · price × 206.9M shares outstanding
- 52-week range
- $21.86 – $45.42 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $47.98M USDMedian day 1.24M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IMVT · Home | $31.77 USD | -1.40 (-4.2%) | 702,865 | $32.07 | $32.77 | $31.62 | $33.17 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMVT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $31.77 | -1.40 | -4.2% | $32.07 | $32.77 | $31.62 | 702,865 | |
| $33.17 | -0.04 | -0.1% | $33.07 | $34.23 | $32.59 | 907,602 | |
| $33.21 | -0.07 | -0.2% | $33.17 | $33.82 | $32.45 | 926,704 | |
| $33.28 | -0.90 | -2.6% | $33.86 | $34.53 | $33.04 | 1,053,974 | |
| $34.18 | -0.87 | -2.5% | $34.24 | $34.77 | $33.94 | 864,692 | |
| $35.05 | -1.99 | -5.4% | $36.92 | $36.92 | $34.86 | 1,182,848 | |
| $37.04 | +1.33 | +3.7% | $35.77 | $37.59 | $35.52 | 1,712,162 | |
| $35.71 | +0.56 | +1.6% | $35.15 | $35.96 | $34.83 | 1,644,281 | |
| $35.15 | +4.62 | +15.1% | $33.00 | $35.61 | $32.81 | 3,978,245 | |
| $30.53 | +2.14 | +7.5% | $28.73 | $30.60 | $28.34 | 2,658,239 | |
| $28.39 | -1.51 | -5.1% | $29.78 | $29.83 | $28.12 | 1,119,632 | |
| $29.90 | +0.86 | +3.0% | $29.82 | $29.93 | $28.50 | 1,109,836 | |
| $29.04 | +0.63 | +2.2% | $28.70 | $29.48 | $28.42 | 1,079,583 | |
| $28.41 | -0.76 | -2.6% | $29.32 | $29.64 | $28.38 | 1,268,029 | |
| $29.17 | -0.47 | -1.6% | $29.49 | $29.78 | $28.76 | 1,165,416 | |
| $29.64 | +0.22 | +0.7% | $29.56 | $30.07 | $29.33 | 1,399,285 | |
| $29.42 | +0.54 | +1.9% | $28.50 | $29.47 | $28.44 | 1,241,925 | |
| $28.88 | +0.71 | +2.5% | $28.06 | $28.96 | $28.01 | 1,057,999 | |
| $28.17 | -0.24 | -0.8% | $28.46 | $28.50 | $27.63 | 1,195,295 | |
| $28.41 | -0.69 | -2.4% | $28.93 | $28.93 | $28.14 | 641,437 | |
| $29.10 | +0.72 | +2.5% | $28.09 | $29.12 | $27.98 | 1,157,318 | |
| $28.38 | -0.21 | -0.7% | $28.97 | $29.18 | $28.05 | 1,494,805 | |
| $28.59 | +0.97 | +3.5% | $27.76 | $29.14 | $27.62 | 1,448,985 | |
| $27.62 | +0.89 | +3.3% | $27.12 | $27.84 | $26.53 | 1,375,274 | |
| $26.73 | -0.78 | -2.8% | $27.42 | $27.42 | $26.28 | 1,463,200 | |
| $27.51 | -0.39 | -1.4% | $28.03 | $28.33 | $27.48 | 1,649,300 | |
| $27.90 | -0.81 | -2.8% | $28.46 | $28.79 | $27.83 | 1,773,500 | |
| $28.71 | -0.77 | -2.6% | $29.37 | $29.64 | $28.70 | 1,242,700 | |
| $29.48 | -0.99 | -3.2% | $30.17 | $30.60 | $28.61 | 2,241,900 | |
| $30.47 | +0.21 | +0.7% | $30.25 | $30.64 | $30.07 | 1,494,800 | |
| $30.26 | -1.78 | -5.6% | $31.40 | $31.50 | $29.80 | 1,755,400 | |
| $32.04 | -0.07 | -0.2% | $31.72 | $32.75 | $31.58 | 1,131,400 | |
| $32.11 | -1.14 | -3.4% | $33.51 | $33.51 | $31.36 | 1,674,000 | |
| $33.25 | -0.37 | -1.1% | $33.99 | $33.99 | $32.95 | 1,103,200 | |
| $33.62 | -0.03 | -0.1% | $34.11 | $34.24 | $33.21 | 1,022,200 | |
| $33.65 | -0.13 | -0.4% | $33.56 | $34.60 | $33.30 | 1,671,800 | |
| $33.78 | +0.32 | +1.0% | $33.62 | $34.20 | $33.12 | 1,433,900 | |
| $33.46 | -0.03 | -0.1% | $33.43 | $33.53 | $32.45 | 1,311,400 | |
| $33.49 | +0.19 | +0.6% | $32.93 | $33.77 | $32.65 | 1,229,300 | |
| $33.30 | -0.70 | -2.1% | $34.00 | $34.22 | $33.17 | 2,350,000 | |
| $34.00 | -0.54 | -1.6% | $34.21 | $34.55 | $33.35 | 1,479,300 | |
| $34.54 | -2.75 | -7.4% | $36.35 | $37.00 | $33.60 | 3,652,800 | |
| $37.29 | +0.11 | +0.3% | $37.38 | $38.15 | $36.84 | 2,255,200 | |
| $37.18 | +0.23 | +0.6% | $37.23 | $37.49 | $36.55 | 1,031,400 | |
| $36.95 | -0.70 | -1.9% | $37.52 | $38.35 | $36.80 | 2,943,800 | |
| $37.65 | +1.27 | +3.5% | $37.09 | $37.68 | $36.54 | 1,330,600 | |
| $36.38 | -0.27 | -0.7% | $36.75 | $37.22 | $36.11 | 1,169,200 | |
| $36.65 | -1.01 | -2.7% | $37.43 | $37.50 | $36.19 | 1,573,800 | |
| $37.66 | +0.30 | +0.8% | $37.25 | $38.03 | $37.00 | 1,110,900 | |
| $37.36 | -0.74 | -1.9% | $38.62 | $38.93 | $37.19 | 1,031,900 | |
| $38.10 | -0.65 | -1.7% | $38.18 | $38.31 | $37.53 | 1,083,400 | |
| $38.75 | -0.82 | -2.1% | $39.11 | $39.73 | $38.67 | 1,023,700 | |
| $39.57 | +0.32 | +0.8% | $38.59 | $40.56 | $38.34 | 1,513,700 | |
| $39.25 | +0.13 | +0.3% | $39.44 | $39.73 | $38.73 | 765,600 | |
| $39.12 | -0.37 | -0.9% | $39.48 | $39.48 | $38.64 | 1,235,400 | |
| $39.49 | -0.41 | -1.0% | $40.15 | $40.96 | $38.61 | 1,331,000 | |
| $39.90 | -0.92 | -2.3% | $40.60 | $41.37 | $39.20 | 1,585,500 | |
| $40.82 | -0.38 | -0.9% | $40.96 | $41.28 | $39.91 | 1,391,700 | |
| $41.20 | -2.62 | -6.0% | $43.27 | $43.38 | $41.09 | 1,082,500 | |
| $43.82 | -0.07 | -0.2% | $43.60 | $43.95 | $43.14 | 868,500 | |
| $43.89 | +0.39 | +0.9% | $43.54 | $44.21 | $42.65 | 852,400 | |
| $43.50 | +0.18 | +0.4% | $43.79 | $44.50 | $43.27 | 1,346,827 | |
| $43.32 | -1.05 | -2.4% | $44.00 | $44.04 | $43.20 | 1,189,318 | |
| $44.37 | +0.02 | 0.0% | $44.85 | $45.12 | $44.08 | 846,600 | |
| $44.35 | -0.61 | -1.4% | $44.37 | $44.69 | $43.42 | 954,400 |
- Ticker
- NASDAQ:IMVT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
Latest earnings call · Nov 9, 2026
Immunovant (NASDAQ:IMVT) Q2 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 68 slides
Latest news
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
Nov 9, 2026
Closed $35.15 (+15.1%) on Nov 9, 2026
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Oct 21, 2026
Closed $28.38 (-0.7%) on Oct 21, 2026
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Sep 23, 2026
Closed $34.54 (-7.4%) on Sep 23, 2026
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Jul 23, 2026
Closed $39.41 (+0.1%) on Jul 24, 2026
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
May 20, 2026
Closed $35.56 (+35.3%) on May 20, 2026
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026
Closed $28.65 (-1.4%) on May 12, 2026
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Apr 2, 2026
Closed $24.50 (-2.4%) on Apr 2, 2026
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Feb 6, 2026
Closed $27.05 (+12.4%) on Feb 6, 2026
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Jan 23, 2026
Closed $26.60 (+2.3%) on Jan 26, 2026
Immunovant Announces Pricing of $550 Million Common Stock Financing
Dec 11, 2025
Closed $24.81 (+5.3%) on Dec 11, 2025
Immunovant, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 10 in the last 12 months · 90 in all · newest Nov 9, 2026 · oldest 2019
- Calls
- 8 calls with a replay · 8 with a transcript · latest Nov 9, 2026
- Decks
- 30 decks · latest November 2026
Where Immunovant, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IMVT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:IMVT | BOATS | United States | USD |
Valuation
EV/sales 825× against a median of 33.4×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $5.85B USD
- P/E
- Loss
- EV/sales
- 825×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 10.0×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.46
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Immunovant, Inc. · NASDAQ:IMVT | US$6.57B | US$5.85B | n/a | 825× | n/a | 10.0× | n/a | 0.0× | 1.46 |
| CG Oncology, Inc. · NASDAQ:CGON | US$7.10B | US$6.12B | n/a | 992× | n/a | 7.2× | n/a | 0.0× | 0.83 |
| Cytokinetics, Incorporated · NASDAQ:CYTK | US$7.07B | US$6.36B | n/a | 56.2× | n/a | n/a | −686.6% | n/a | 0.93 |
| Axsome Therapeutics, Inc. · NASDAQ:AXSM | US$6.80B | US$6.68B | n/a | 7.7× | n/a | 64.5× | −18.2% | 1.8× | 0.69 |
| Akeso, Inc. · HKEX:9926 | US$6.66B | US$6.04B | n/a | 13.5× | n/a | 5.2× | −36.4% | 0.6× | n/a |
| Oruka Therapeutics, Inc. · NASDAQ:ORKA | US$6.50B | US$5.58B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.30 |
| ImmunityBio, Inc. · NASDAQ:IBRX | US$6.40B | US$6.10B | n/a | 33.4× | n/a | n/a | −607.8% | n/a | 1.50 |
| Kodiak Sciences Inc · NASDAQ:KOD | US$6.35B | US$6.31B | n/a | n/a | n/a | 505× | n/a | 3.7× | 1.58 |
| Abivax SA · EURONEXT:ABVX | US$6.05B | US$5.60B | n/a | n/a | n/a | 15.1× | n/a | 0.0× | n/a |
| Scholar Rock Holding Corporation · NASDAQ:SRRK | US$5.87B | US$5.65B | n/a | 9,921× | n/a | 34.8× | n/a | 1.2× | 0.91 |
| Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWR | US$5.85B | US$4.66B | n/a | 10.3× | n/a | 116× | −160.6% | 0.0× | 1.34 |
| Median of the others | US$6.45B | US$6.07B | 33.4× | 24.9× | −160.6% | 0.3× | 1.12 |
Forecasts
11 strong buy · 2 buy · 4 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 48.31 USD · Analysts' mean
- EPS, year to Mar 2027
- -2.68 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Eric Venker | Chief Executive Officer |
| Tiago Girão | Chief Financial Officer |
| Melanie Gloria | Chief Operating Officer |
| Christopher Van Tuyl | Chief Legal Officer and Corporate Secretary |
| Chedvi Levin-Sister | Vice President of Finance |
| Christine Blodgett | Senior Vice President of Human Resources |
| Dawn Gardner | Vice President, Program Management |
| Elena Grigoryeva | Senior Vice President, Head of Clinical Development |
| Harry Berlanga | VP, CMC & Distribution Quality |
| Philip Tedeschi | Vice President, Translational Sciences and Clinical Laboratories |
| Rod Saponjic | Vice President of Clinical Operations |
| Sheetal Patel | Senior Vice President, Clinical Development |
| Frank Torti | Executive Chairman |
| Jay S. Stout | Chief Technology Officer |
| Ruby Grewal | Chief Strategy Officer |
Board
| Director | Role |
|---|---|
| Frank Torti | Executive Chairman |
| Andrew Fromkin | Member of the Board of Directors |
| Atul Pande | Member of the Board of Directors |
| Douglas Hughes | Member of the Board of Directors |
| Eric Venker | Chief Executive Officer |
| Jake Bauer | Board Member |
| Robert Susman | Member of the Board of Directors |
Events
Calls
| Call | When | Status |
|---|---|---|
| Immunovant (NASDAQ:IMVT) Q2 2026 Earnings Call | Mon, Nov 09, 2026 · 8:00 AM ET | Replay |
| Immunovant (NASDAQ:IMVT) Q1 2026 Earnings Call | Thu, Aug 06, 2026 · 8:00 AM ET | Replay |
| Immunovant (NASDAQ:IMVT) Q3 2025 Earnings Call | Fri, Feb 06, 2026 · 8:00 AM ET | Replay |
| Immunovant (NASDAQ:IMVT) Q2 2025 Earnings Call | Mon, Nov 10, 2025 · 8:00 AM ET | Replay |
| Immunovant (NASDAQ:IMVT) Q1 2025 Earnings Call | Mon, Aug 11, 2025 · 8:00 AM ET | Replay |
| Immunovant (NASDAQ:IMVT) Q4 2024 Earnings Call | Thu, May 29, 2025 · 8:00 AM ET | Replay |
| Immunovant (NASDAQ:IMVT) Q4 2022 Earnings Call | Wed, Jun 08, 2022 · 8:00 AM ET | Replay |
| Immunovant (NASDAQ:IMVT) Q2 2022 Earnings Call | Mon, Aug 09, 2021 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2027 | Nov 9, 2026 · Before open | +15.1% |
| Q1 2027 | Aug 6, 2026 · Before open | +1.2% |
| Q4 2026 | May 20, 2026 · Before open | +35.3% |
| Q3 2026 | Feb 6, 2026 · Before open | +12.4% |
| Q2 2026 | Nov 10, 2025 · Before open | +0.1% |
| Q1 2026 | Aug 11, 2025 · Before open | −4.5% |
| Q4 2025 | May 29, 2025 | +5.3% |
| Q3 2025 | Feb 6, 2025 · Before open | −9.6% |
| Q2 2025 | Nov 7, 2024 · Before open | −4.7% |
| Q1 2025 | Aug 6, 2024 · After close | −3.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | May 29, 2024 · After close | −10.7% |
| Q3 2024 | Feb 12, 2024 · Before open | +3.4% |
| Q2 2024 | Nov 9, 2023 · Before open | −6.2% |
| Q1 2024 | Aug 10, 2023 · Before open | +6.7% |
| Q4 2023 | May 22, 2023 · Before open | +12.0% |
| Q3 2023 | Feb 3, 2023 · Before open | −3.0% |
| Q2 2023 | Nov 4, 2022 · Before open | +1.1% |
| Q1 2023 | Aug 5, 2022 · Before open | +8.7% |
| Q4 2022 | Jun 8, 2022 · Before open | −8.2% |
| Q3 2022 | Feb 4, 2022 · Before open | −1.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 68 slides | November 2026 |
| Investor Presentation (September 2026) | Investor deck | 62 slides | September 2026 |
| Q1 2026 Earnings Presentation | Earnings | 69 slides | Aug 6, 2026 |
| Technical Presentation (September 2025) | Technical | 23 slides | Sep 3, 2025 |
| Corporate Update (April 2025) | Corporate update | 27 slides | Apr 21, 2025 |
| Corporate Update (March 2025) | Corporate update | 34 slides | Mar 19, 2025 |
| 2025 J.P. Morgan Healthcare Conference | Conference | 21 slides | Jan 14, 2025 |
| Investor Day (2025) | Investor day | 56 slides | 2025 |
| Corporate Update (November 2024) | Corporate update | 29 slides | Nov 7, 2024 |
| Corporate Update (September 2024) | Corporate update | 32 slides | Sep 9, 2024 |
All 30 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$550M · US$21 a share · Leerink Partners Dealers: Leerink Partners (lead) Buyers: Roivant Sciences Ltd. Insiders: Roivant Sciences Ltd., the controlling stockholder, has agreed to purchase shares in the offering Use of proceeds: Fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 in Graves’ Disease | Dec 11, 2025 |
| Private placement of shares of common stock Announced: about US$450M · US$20 a share Buyers: Roivant Use of proceeds: Advancement of its development pipeline, working capital and other general corporate purposes | Jan 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Health Sciences Acquisitions Corp, a blank check company (SPAC). Priced at US$10.00 a unit on May 9, 2019.
- Price
- US$10.00 a unit
- Units offered
- 10,000,000 units
- Offering size
- US$100 million
- Underwriters' option
- Up to 1,500,000 more units
- Listing
- HSACU on the Nasdaq Capital Market
- Underwriters
- Chardan, UBS Investment Bank · In the order on the cover
- Units delivered
- On or about May 14, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 23, 2019 |
| Filed publicly | Apr 16, 2019 |
| Amended twice | Newest May 3, 2019 |
| Shares registered with an exchange | May 9, 2019 |
| Declared effective by the SEC | May 9, 2019 |
| Final prospectus, with the price | May 10, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 10, 2019 |
| EFFECT · Notice that a registration is effective | May 9, 2019 |
| CERT · Exchange's certificate of listing | May 9, 2019 |
| CORRESP · Letter to the SEC | May 9, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | May 9, 2019 |
| CORRESP · Letter to the SEC | May 8, 2019 |
| CORRESP · Letter to the SEC | May 3, 2019 |
| S-1/A · Registration statement, amended | May 3, 2019 |
| UPLOAD · Letter from the SEC | May 1, 2019 |
| S-1/A · Registration statement, amended | Apr 29, 2019 |
All 15 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Apr 16, 2019 |
| DRS/A · Draft registration statement, amended | Feb 26, 2019 |
| DRSLTR · Letter to the SEC with a draft | Feb 25, 2019 |
| UPLOAD · Letter from the SEC | Feb 11, 2019 |
| DRS · Draft registration statement | Jan 23, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed May 10, 2019
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Cost of revenue | 409.0K | 377.0K | 231.0K | 1.32M | 1.23M | 998.0K | 21.0K | |||
| Gross profit | -409.0K | -377.0K | -231.0K | -1.32M | -1.23M | -998.0K | -21.0K | |||
| Research and development | 456.7M | 360.9M | 212.9M | 160.3M | 101.8M | 68.6M | 47.9M | 25.7M | 135.3M | |
| Selling, general and administrative | 76.2M | 77.2M | 57.3M | 48.0M | 54.2M | 39.5M | 18.2M | 2.69M | 1.48M | |
| Operating income | -532.9M | -438.2M | -270.2M | -208.3M | -156.0M | -108.1M | -59.7M | -450 | -450 | -136.7M |
| Depreciation and amortization | 409.0K | 377.0K | 231.0K | 193.0K | 126.0K | 65.0K | 21.0K | 10.0K | 136.7M | |
| EBITDA | -532.5M | -437.8M | -270.0M | -208.1M | -155.9M | -108.1M | -59.7M | 9.55K | 0 | |
| Interest expense | 49.9M | 12.5M | 655.0K | 0 | 625.0K | 0 | 0 | 0 | ||
| Income before tax | -505.4M | -412.9M | -258.8M | -211.0M | -156.8M | -107.8M | -66.3M | -28.6M | -450 | -136.7M |
| Income tax | 215.0K | 891.0K | 567.0K | 9.00K | -84.0K | -358.0K | 97.0K | 19.0K | ||
| Net income | -505.6M | -413.8M | -259.3M | -211.0M | -156.7M | -107.4M | -66.4M | -28.6M | -450 | -136.7M |
| Earnings per share, basic | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | -1.29 | -13.67 | |
| Earnings per share, diluted | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | -1.29 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 902.1M | 714.0M | 635.4M | 376.5M | 493.8M | 400.1M | 100.6M | 6.99M | |
| Receivables | 1.13M | 2.08M | 5.34M | 700.0K | 12.2M | 596.0K | 3.04M | 2.96M | |
| Inventory | -24.9M | 0 | 0 | 0 | |||||
| Current assets | 948.8M | 767.7M | 665.8M | 404.3M | 512.9M | 409.0M | 109.1M | 12.6M | 113.2K |
| Property, plant and equipment | 443.0K | 844.0K | 462.0K | 333.0K | 330.0K | 201.0K | 65.0K | 54.0K | |
| Total assets | 957.0M | 776.2M | 666.4M | 405.8M | 515.6M | 412.5M | 109.4M | 13.8M | 113.2K |
| Accounts payable | 7.54M | 17.7M | 7.16M | 1.35M | 18.6M | 2.43M | 1.19M | 206.0K | 1.14M |
| Current liabilities | 104.4M | 68.8M | 48.6M | 43.3M | 44.5M | 18.8M | 15.3M | 300.4K | 1.61M |
| Total debt | 72.0K | 98.0K | 138.0K | 1.22M | 2.36M | 3.42M | 3.19M | 300.0K | |
| Total liabilities | 104.4M | 68.8M | 48.6M | 43.3M | 45.7M | 21.0M | 15.3M | 6.49M | 1.61M |
| Shareholders' equity | 852.6M | 707.4M | 617.8M | 362.5M | 469.8M | 391.5M | 94.1M | 7.34M | -1.50M |
| Shares outstanding | 203.9M | 170.1M | 145.6M | 130.3M | 116.5M | 98.0M | 54.7M | 38.6M | 10.0M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -407.3M | -375.9M | -214.2M | -188.2M | -106.1M | -83.3M | -53.4M | -28.5M | -128.3M | |
| Capital spending | -8.00K | -759.0K | -360.0K | -197.0K | -254.0K | -210.0K | -31.0K | -52.0K | 0 | -52.0K |
| Free cash flow | -407.3M | -376.6M | -214.6M | -188.4M | -106.4M | -83.5M | -53.4M | -28.6M | -128.3M | |
| Cash from investing | -8.00K | -759.0K | -360.0K | -197.0K | -254.0K | -210.0K | -31.0K | -52.0K | -52.0K | |
| Cash from financing | 595.8M | 454.5M | 472.4M | 70.9M | 200.1M | 383.1M | 147.0M | 35.6M | 325.0K | 128.3M |
| Share buybacks | 70.9M | 200.0M | 385.2M | 1.00K | 25.0K | 25.0K | ||||
| Change in cash | 188.1M | 78.6M | 258.8M | -117.3M | 93.7M | 299.6M | 93.6M | 6.99M | 325.0K | 6.99M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| S-3ASR · Registration statement | Nov 9, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Jul 22, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 22, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| 10-K · Annual report | May 20, 2026 | Annual report | SEC |
| 8-K · Current report | May 20, 2026 | Results | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 10, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Feb 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2025 | Current report | SEC |
| 424B5 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| FWP · Free writing prospectus | Dec 10, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 26, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 21, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| 8-K · Current report | Aug 28, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 29, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Jul 9, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 9, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 9, 2025 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Jun 25, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 3, 2025 | Other filings | SEC |
| 10-K · Annual report | May 29, 2025 | Annual report | SEC |
| 8-K · Current report | May 29, 2025 | Results | SEC |
| 144 · Notice of proposed sale | May 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Apr 30, 2025 | Offer document | SEC |
| 3 · Initial statement of ownership | Apr 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 21, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 21, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 26, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 19, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 7, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 11, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Feb 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 6, 2025 | Results | SEC |
| 8-K · Current report | Jan 24, 2025 | Current report | SEC |
| 424B3 · Prospectus | Jan 24, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| D | Jan 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 14, 2025 | Current report | SEC |
| 8-K · Current report | Jan 13, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 20, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2024 | Meeting outcome | SEC |
This page holds 200 of 653 filings. Open Filings
Cap table
Built by 6ix from Immunovant, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 206,947,758
- Fully diluted
- 206,947,758
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 206,947,758 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 206,947,758 |
| Sep 30, 2026 | 206,785,540 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Myrtle S Potter Other companies: Ginkgo Bioworks Holdings, Inc. (Director · Since at least Jun 13, 2024); Guardant Health, Inc. (Director · Since at least Oct 15, 2021); Arbutus Biopharma Corporation (Director · Oct 18, 2018 – Aug 17, 2019 · Past); Sio Gene Therapies Inc (Director · Sep 26, 2018 – Apr 15, 2019 · Past); Urovant Sciences Ltd (Director · Sep 26, 2018 – Mar 29, 2021 · Past); Myovant Sciences Ltd (Director · Sep 20, 2018 – Mar 10, 2023 · Past); Axsome Therapeutics, Inc. (Director · Jun 16, 2017 – Jun 7, 2019 · Past); Insmed Incorporated (Director · Dec 11, 2014 – May 15, 2018 · Past); Everyday Health Inc (Director · Mar 27, 2014 – Dec 3, 2016 · Past); Rite Aid Corporation (Director · Nov 29, 2013 – Oct 3, 2017 · Past) | Director · Dec 18, 2019 – Dec 18, 2019 · Past |
| Pedro P Granadillo Other companies: Rocket Pharmaceuticals, Inc. (Director · Since at least Jan 4, 2018); Orchestra BioMed Holdings, Inc. (Director · Aug 3, 2020 – Aug 3, 2020 · Past); NPS Pharmaceuticals Inc (Director · Nov 17, 2010 – Feb 21, 2015 · Past); Dendreon Corp (Director · Oct 7, 2009 – Jan 3, 2014 · Past); Capricor Therapeutics, Inc. (Director · Oct 16, 2007 – May 10, 2011 · Past); Haemonetics Corporation (Director · May 5, 2006 – Nov 8, 2018 · Past); First Indiana Corp (Director · Jan 3, 2006 – Jan 2, 2008 · Past) | Director · May 9, 2019 – May 9, 2019 · Past |
| Eric Venker Other companies: Roivant Sciences Ltd. (Roivant President and Immunovant CEO · Since at least Oct 1, 2021); Arbutus Biopharma Corporation (Director · Feb 18, 2020 – Feb 18, 2020 · Past); Sio Gene Therapies Inc (Director · Feb 17, 2020 – Feb 17, 2020 · Past) | Chief Executive Officer · Since at least Feb 18, 2020 |
| Sukumar Nagendran Other companies: Taysha Gene Therapies, Inc. (Director · Since at least Sep 23, 2020); Solid Biosciences Inc. (President, Head of Research & Development, Taysha Gene Therapies · Since at least Sep 12, 2018); AveXis Inc (Sr. VP & Chief Medical Officer · Feb 10, 2016 – May 15, 2018 · Past) | Director · May 9, 2019 – May 9, 2019 · Past |
| Jake Bauer Other companies: BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Aug 11, 2025); Enliven Therapeutics, Inc. (Chairman of the Board of Directors · Since at least Feb 23, 2023) | Director · Since at least Apr 18, 2025 |
| Mark S Levine Other companies: 908 Devices Inc. (Chief Legal and Admin. Officer · Since at least Feb 26, 2026); Flexion Therapeutics Inc (General Counsel · Jan 5, 2021 – Nov 19, 2021 · Past) | Chief Legal Officer · Jan 19, 2022 – Nov 20, 2024 · Past |
| Naveen Yalamanchi Other companies: Orchestra BioMed Holdings, Inc. (Chief Financial Officer, Director · Aug 3, 2020 – Aug 3, 2020 · Past); Rocket Pharmaceuticals, Inc. (Director · Jan 4, 2018 – Jun 13, 2024 · Past) | Vice President and CFO, Director · May 9, 2019 – May 9, 2019 · Past |
| Robert K Zeldin Other companies: MeiraGTx Holdings plc (CHIEF MEDICAL OFFICER · Since at least Aug 3, 2020); Acceleron Pharma Inc (EVP & Chief Medical Officer · Jun 29, 2018 – Jan 25, 2019 · Past) | Chief Medical Officer · Dec 18, 2019 – Dec 18, 2019 · Past |
| Alice Lee Other companies: Orchestra BioMed Holdings, Inc. (VP Operations, Sec & Treasurer · Aug 3, 2020 – Aug 4, 2020 · Past) | VPO, Secretary and Treasurer · May 9, 2019 – May 9, 2019 · Past |
| Douglas Hughes Other companies: Eargo, Inc. (Director · Oct 15, 2020 – Nov 22, 2022 · Past) | Member of the Board of Directors · Since at least Dec 18, 2019 |
All 39 people
| Person | Seat |
|---|---|
| Frank Torti Other companies: Roivant Sciences Ltd. (President and Vant Chair · Since at least Jul 29, 2025) | Director · Since at least Apr 1, 2025 |
| Frank Torti Other companies: Roivant Sciences Ltd. (Vant Chair & President · Since at least May 20, 2026) | Executive Chairman · Since at least Apr 9, 2026 |
| George Migausky Other companies: Regenxbio Inc. (Chairman of the Board · Since at least May 31, 2024) | Director · Dec 1, 2023 – Apr 1, 2025 · Past |
| Jake Bauer Other companies: BridgeBio Oncology Therapeutics, Inc. (Chairman · Since at least Aug 11, 2025) | Board Member · Since at least Apr 9, 2026 |
| Jay S. Stout Other companies: Aravive Inc (SVP, Technical Operations · Oct 6, 2017 – Apr 24, 2018 · Past) | Chief Technology Officer · Since at least Apr 17, 2023 |
| Mark Schoenebaum Other companies: TG Therapeutics, Inc. (Director · Apr 16, 2012 – Jun 26, 2018 · Past) | Director · May 9, 2019 – May 9, 2019 · Past |
| Melanie Gloria Other companies: Acelyrin, Inc. (Chief Operating Officer · May 4, 2023 – May 23, 2024 · Past) | Chief Operating Officer · Since at least Nov 7, 2024 |
| Stephanie A Sirota Other companies: Orchestra BioMed Holdings, Inc. (VP of Corp Stratege and Comm · Aug 3, 2020 – Aug 4, 2020 · Past) | VP of CSC · May 9, 2019 – May 9, 2019 · Past |
| Aileen Ilaria | Vice President, Clinical Operations – Global Site Management · Nov 4, 2026 – Nov 4, 2026 · Past |
| Andrew Fromkin | Member of the Board of Directors · Since at least May 29, 2026 |
| Atul Pande | Director · Since at least Apr 1, 2025 |
| Cassandra Pauyo | Vice President, Data Management · Nov 4, 2026 – Nov 4, 2026 · Past |
| Chedvi Levin-Sister | Vice President of Finance · Since at least Nov 4, 2026 |
| Christine Blodgett | Senior Vice President of Human Resources · Since at least Nov 4, 2026 |
| Christopher Van Tuyl | Chief Legal Officer and Corporate Secretary · Since at least Dec 16, 2024 |
| Dawn Gardner | Vice President, Program Management · Since at least Nov 4, 2026 |
| Elena Grigoryeva | Senior Vice President, Head of Clinical Development · Since at least Nov 4, 2026 |
| Eva Renee Barnett | Chief Financial Officer · Oct 4, 2021 – Apr 16, 2025 · Past |
| Harry Berlanga | VP, CMC & Distribution Quality · Since at least Nov 4, 2026 |
| Julia G Butchko | Chief Development Officer · Dec 18, 2019 – Aug 21, 2024 · Past |
| Luciano Pollastrini | Senior Vice President, CMC Technical Operations · Nov 4, 2026 – Nov 4, 2026 · Past |
| Michael Geffner | Chief Medical Officer · Since at least Jan 16, 2024 |
| Philip Tedeschi | Vice President, Translational Sciences and Clinical Laboratories · Since at least Nov 4, 2026 |
| Robert Susman | Director · Since at least Apr 18, 2025 |
| Rod Saponjic | Vice President of Clinical Operations · Since at least Nov 4, 2026 |
| Ruby Grewal | Chief Strategy Officer · Since at least Nov 4, 2026 |
| Sheetal Patel | Senior Vice President, Clinical Development · Since at least Nov 4, 2026 |
| Tiago Girão | Chief Financial Officer · Since at least May 29, 2025 |
| Yan Zheng | Senior Vice President Biostatistics, Programming & Data Management · Nov 4, 2026 – Nov 4, 2026 · Past |
Log in to ask 6ix AI your own questions about Immunovant, Inc.